Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ischemic Preconditioning, Myocardial | 8 | 2005 | 22 | 0.950 |
Why?
|
| Myocardial Ischemia | 5 | 2007 | 112 | 0.930 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2007 | 26 | 0.770 |
Why?
|
| Insecticides | 3 | 2006 | 30 | 0.670 |
Why?
|
| Myocardium | 5 | 2007 | 265 | 0.670 |
Why?
|
| Protein Precursors | 2 | 2007 | 75 | 0.560 |
Why?
|
| Receptors, Opioid | 2 | 2007 | 14 | 0.490 |
Why?
|
| Diazepam | 2 | 2006 | 10 | 0.480 |
Why?
|
| Dichlorvos | 2 | 2006 | 15 | 0.460 |
Why?
|
| Rats | 13 | 2007 | 1911 | 0.420 |
Why?
|
| Diphenhydramine | 2 | 2003 | 9 | 0.410 |
Why?
|
| Histamine H1 Antagonists | 2 | 2003 | 10 | 0.410 |
Why?
|
| Fluorocarbons | 4 | 2002 | 34 | 0.410 |
Why?
|
| Jejunum | 2 | 2002 | 14 | 0.400 |
Why?
|
| Liquid Ventilation | 2 | 2002 | 4 | 0.370 |
Why?
|
| Rabbits | 8 | 2006 | 326 | 0.370 |
Why?
|
| Hypothermia, Induced | 2 | 2001 | 40 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 4 | 2006 | 739 | 0.350 |
Why?
|
| Ischemia | 2 | 2002 | 200 | 0.340 |
Why?
|
| Animals | 27 | 2020 | 19705 | 0.330 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2002 | 27 | 0.330 |
Why?
|
| Management Quality Circles | 1 | 2009 | 1 | 0.320 |
Why?
|
| Organizational Case Studies | 1 | 2009 | 39 | 0.320 |
Why?
|
| Random Allocation | 6 | 2006 | 190 | 0.310 |
Why?
|
| Ursidae | 2 | 2020 | 12 | 0.310 |
Why?
|
| Enkephalin, Methionine | 2 | 2006 | 9 | 0.310 |
Why?
|
| Rats, Wistar | 8 | 2003 | 179 | 0.300 |
Why?
|
| Blood Transfusion | 2 | 1999 | 150 | 0.300 |
Why?
|
| Total Quality Management | 1 | 2008 | 56 | 0.300 |
Why?
|
| Enkephalins | 1 | 2007 | 16 | 0.290 |
Why?
|
| Opioid Peptides | 1 | 2007 | 1 | 0.290 |
Why?
|
| Efficiency, Organizational | 1 | 2008 | 93 | 0.280 |
Why?
|
| Naloxone | 3 | 2004 | 57 | 0.280 |
Why?
|
| Trauma Centers | 1 | 2008 | 114 | 0.280 |
Why?
|
| Physical Exertion | 1 | 2007 | 79 | 0.280 |
Why?
|
| Heart | 4 | 2007 | 275 | 0.280 |
Why?
|
| Emergency Service, Hospital | 3 | 2013 | 1024 | 0.270 |
Why?
|
| Disease Models, Animal | 9 | 2007 | 2060 | 0.270 |
Why?
|
| Glycopyrrolate | 2 | 2006 | 23 | 0.270 |
Why?
|
| Xylazine | 1 | 2006 | 3 | 0.260 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 50 | 0.260 |
Why?
|
| Antidotes | 1 | 2006 | 20 | 0.250 |
Why?
|
| Morphine | 1 | 2006 | 51 | 0.250 |
Why?
|
| Ketamine | 1 | 2006 | 32 | 0.250 |
Why?
|
| Hypothermia | 2 | 2001 | 19 | 0.220 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 727 | 0.220 |
Why?
|
| Narcotics | 1 | 2004 | 53 | 0.220 |
Why?
|
| Carotid Arteries | 2 | 2001 | 62 | 0.220 |
Why?
|
| Apnea | 1 | 2004 | 30 | 0.220 |
Why?
|
| Muscle Relaxants, Central | 1 | 2003 | 12 | 0.220 |
Why?
|
| Tobramycin | 1 | 2003 | 6 | 0.220 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 31 | 0.220 |
Why?
|
| In Vitro Techniques | 5 | 2002 | 476 | 0.210 |
Why?
|
| Klebsiella Infections | 1 | 2003 | 21 | 0.210 |
Why?
|
| Ventricular Fibrillation | 2 | 2001 | 98 | 0.210 |
Why?
|
| Hibernation | 2 | 2020 | 10 | 0.210 |
Why?
|
| Neutron Activation Analysis | 1 | 2003 | 3 | 0.210 |
Why?
|
| Iohexol | 1 | 2003 | 16 | 0.210 |
Why?
|
| Muscarinic Antagonists | 1 | 2003 | 32 | 0.200 |
Why?
|
| Organophosphate Poisoning | 1 | 2002 | 14 | 0.200 |
Why?
|
| Pneumonia, Bacterial | 1 | 2003 | 88 | 0.200 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 56 | 0.200 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 1 | 2002 | 2 | 0.200 |
Why?
|
| Receptors, Opioid, delta | 1 | 2002 | 5 | 0.200 |
Why?
|
| Potassium Channels | 1 | 2002 | 53 | 0.190 |
Why?
|
| Vaccines | 1 | 2023 | 95 | 0.190 |
Why?
|
| Swine | 4 | 2007 | 360 | 0.190 |
Why?
|
| Arm Injuries | 1 | 2001 | 11 | 0.190 |
Why?
|
| Leg Injuries | 1 | 2001 | 16 | 0.190 |
Why?
|
| Reperfusion Injury | 1 | 2002 | 49 | 0.190 |
Why?
|
| Myocardial Reperfusion | 4 | 2006 | 24 | 0.190 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 149 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2007 | 577 | 0.180 |
Why?
|
| Ventricular Function, Left | 2 | 2000 | 258 | 0.180 |
Why?
|
| Rewarming | 1 | 2001 | 7 | 0.180 |
Why?
|
| Resuscitation | 1 | 2001 | 70 | 0.180 |
Why?
|
| Coronary Vessels | 2 | 2009 | 110 | 0.170 |
Why?
|
| Hemostasis | 1 | 2020 | 18 | 0.170 |
Why?
|
| Patient Discharge | 1 | 2024 | 493 | 0.170 |
Why?
|
| Pharmaceutical Services | 1 | 2020 | 31 | 0.170 |
Why?
|
| Drug Costs | 1 | 2020 | 54 | 0.170 |
Why?
|
| Pain Measurement | 1 | 2001 | 329 | 0.170 |
Why?
|
| Femoral Artery | 1 | 2001 | 103 | 0.170 |
Why?
|
| Patient Readmission | 1 | 2024 | 421 | 0.170 |
Why?
|
| RNA, Viral | 1 | 2021 | 259 | 0.170 |
Why?
|
| Ischemic Preconditioning | 1 | 1999 | 5 | 0.170 |
Why?
|
| Myocardial Infarction | 3 | 2001 | 864 | 0.160 |
Why?
|
| Adenosine | 1 | 1999 | 70 | 0.160 |
Why?
|
| Narcotic Antagonists | 3 | 2007 | 121 | 0.160 |
Why?
|
| Norepinephrine | 1 | 1999 | 98 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2020 | 208 | 0.160 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 66 | 0.160 |
Why?
|
| Male | 17 | 2024 | 27952 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 810 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 145 | 0.150 |
Why?
|
| Pain | 1 | 2001 | 398 | 0.150 |
Why?
|
| Blood Coagulation | 1 | 2017 | 38 | 0.140 |
Why?
|
| Respiration, Artificial | 2 | 1999 | 294 | 0.120 |
Why?
|
| Hemodynamics | 3 | 2001 | 231 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2003 | 3090 | 0.120 |
Why?
|
| Patient Satisfaction | 2 | 2009 | 417 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2003 | 1104 | 0.120 |
Why?
|
| Muscle, Smooth | 2 | 2007 | 137 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2020 | 627 | 0.110 |
Why?
|
| Humans | 16 | 2024 | 59737 | 0.110 |
Why?
|
| Brain | 2 | 2003 | 1495 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2007 | 1472 | 0.100 |
Why?
|
| Perfusion | 3 | 2000 | 80 | 0.090 |
Why?
|
| Body Temperature | 2 | 2001 | 45 | 0.090 |
Why?
|
| Muscle Contraction | 2 | 2002 | 197 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2001 | 592 | 0.080 |
Why?
|
| Connective Tissue | 1 | 2009 | 12 | 0.080 |
Why?
|
| Time Factors | 3 | 2009 | 3629 | 0.080 |
Why?
|
| Hospitals, Community | 1 | 2009 | 69 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 101 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 2 | 2001 | 253 | 0.080 |
Why?
|
| Midwestern United States | 1 | 2008 | 24 | 0.080 |
Why?
|
| Organizational Innovation | 1 | 2009 | 80 | 0.080 |
Why?
|
| Seasons | 2 | 2020 | 123 | 0.080 |
Why?
|
| Intra-Abdominal Fat | 1 | 2009 | 33 | 0.080 |
Why?
|
| Hospitals, Rural | 1 | 2008 | 19 | 0.080 |
Why?
|
| Subcutaneous Fat | 1 | 2009 | 46 | 0.080 |
Why?
|
| Health Plan Implementation | 1 | 2008 | 40 | 0.070 |
Why?
|
| Poisoning | 2 | 2006 | 31 | 0.070 |
Why?
|
| Adipogenesis | 1 | 2009 | 71 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2009 | 173 | 0.070 |
Why?
|
| Kidney | 2 | 2007 | 424 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 171 | 0.070 |
Why?
|
| Epithelium | 1 | 2007 | 96 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 618 | 0.070 |
Why?
|
| Aging | 2 | 2005 | 712 | 0.070 |
Why?
|
| Models, Animal | 2 | 2009 | 224 | 0.070 |
Why?
|
| United States | 4 | 2021 | 7448 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 227 | 0.070 |
Why?
|
| Naltrexone | 1 | 2007 | 77 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 446 | 0.070 |
Why?
|
| Intestines | 1 | 2007 | 159 | 0.070 |
Why?
|
| Adipocytes | 1 | 2009 | 256 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2007 | 590 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 534 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 67 | 0.060 |
Why?
|
| Hospitalization | 1 | 2013 | 1300 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 5147 | 0.060 |
Why?
|
| Cystitis | 1 | 2005 | 9 | 0.060 |
Why?
|
| Staphylococcus | 1 | 2005 | 17 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 227 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 330 | 0.060 |
Why?
|
| Gram-Negative Bacteria | 1 | 2005 | 54 | 0.060 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2005 | 41 | 0.060 |
Why?
|
| Length of Stay | 1 | 2009 | 790 | 0.060 |
Why?
|
| Female | 7 | 2024 | 30925 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2006 | 53 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2005 | 95 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2020 | 2387 | 0.060 |
Why?
|
| Massachusetts | 2 | 2021 | 2027 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 2006 | 81 | 0.060 |
Why?
|
| Middle Aged | 4 | 2020 | 16449 | 0.060 |
Why?
|
| Aged | 4 | 2024 | 13510 | 0.060 |
Why?
|
| Inflammation | 2 | 2009 | 1101 | 0.060 |
Why?
|
| Gene Expression | 1 | 2007 | 811 | 0.060 |
Why?
|
| Transitional Care | 1 | 2024 | 25 | 0.060 |
Why?
|
| Allied Health Personnel | 1 | 2024 | 29 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 3240 | 0.050 |
Why?
|
| Mass Vaccination | 1 | 2023 | 9 | 0.050 |
Why?
|
| Intubation | 1 | 2003 | 11 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2024 | 107 | 0.050 |
Why?
|
| Klebsiella pneumoniae | 1 | 2003 | 26 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2003 | 30 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 50 | 0.050 |
Why?
|
| Ipratropium | 1 | 2003 | 7 | 0.050 |
Why?
|
| Xenon Isotopes | 1 | 2003 | 3 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 50 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2003 | 33 | 0.050 |
Why?
|
| Iodine | 1 | 2003 | 19 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 678 | 0.050 |
Why?
|
| Glyburide | 1 | 2002 | 4 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2002 | 11 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2003 | 101 | 0.050 |
Why?
|
| Potassium Channel Blockers | 1 | 2002 | 24 | 0.050 |
Why?
|
| Mesentery | 1 | 2002 | 15 | 0.050 |
Why?
|
| Splanchnic Circulation | 1 | 2002 | 16 | 0.050 |
Why?
|
| Apoptosis | 1 | 2007 | 1033 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 531 | 0.050 |
Why?
|
| Hydrocarbons, Brominated | 1 | 2002 | 4 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2002 | 21 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 226 | 0.050 |
Why?
|
| Enkephalin, Leucine | 1 | 2001 | 7 | 0.050 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 63 | 0.050 |
Why?
|
| Epinephrine | 1 | 2001 | 41 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 211 | 0.050 |
Why?
|
| Hypoxia | 1 | 2002 | 112 | 0.050 |
Why?
|
| Phenylpropanolamine | 1 | 2001 | 2 | 0.050 |
Why?
|
| Phentolamine | 1 | 2001 | 8 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2006 | 695 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 357 | 0.040 |
Why?
|
| Therapeutic Irrigation | 1 | 2001 | 16 | 0.040 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 20 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 335 | 0.040 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2001 | 15 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 922 | 0.040 |
Why?
|
| Antithrombin III | 1 | 2020 | 14 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2001 | 191 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2020 | 53 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 558 | 0.040 |
Why?
|
| Ventricular Pressure | 1 | 2000 | 30 | 0.040 |
Why?
|
| Heart Rate | 1 | 2001 | 309 | 0.040 |
Why?
|
| Body Weight | 1 | 2001 | 370 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 1999 | 50 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2001 | 161 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 367 | 0.040 |
Why?
|
| Glucose | 1 | 2002 | 444 | 0.040 |
Why?
|
| Kerosene | 1 | 1999 | 1 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 1999 | 76 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2001 | 498 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2020 | 196 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2001 | 255 | 0.040 |
Why?
|
| Adolescent | 3 | 2006 | 5866 | 0.040 |
Why?
|
| Penicillin G | 1 | 1998 | 5 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2020 | 378 | 0.040 |
Why?
|
| Mice | 2 | 2009 | 10316 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2001 | 402 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 1489 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1511 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2020 | 6153 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2006 | 5334 | 0.030 |
Why?
|
| Rats, Inbred F344 | 2 | 2005 | 52 | 0.030 |
Why?
|
| Triage | 1 | 2013 | 108 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 185 | 0.020 |
Why?
|
| Adult | 2 | 2013 | 15771 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2006 | 1289 | 0.020 |
Why?
|
| Infant | 2 | 2006 | 1496 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1038 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2006 | 1802 | 0.020 |
Why?
|
| Cell Shape | 1 | 2009 | 12 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2009 | 13 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2009 | 21 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 54 | 0.020 |
Why?
|
| Adiponectin | 1 | 2009 | 34 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2009 | 87 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2009 | 72 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 81 | 0.020 |
Why?
|
| Adipose Tissue, Brown | 1 | 2009 | 111 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2009 | 146 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 309 | 0.020 |
Why?
|
| Child | 2 | 2006 | 4215 | 0.020 |
Why?
|
| Okadaic Acid | 1 | 2005 | 9 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2005 | 10 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 1142 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 2095 | 0.010 |
Why?
|
| Cell Death | 1 | 2005 | 271 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 660 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 349 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2005 | 305 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 886 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1555 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 46 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2000 | 85 | 0.010 |
Why?
|
| Longevity | 1 | 2001 | 110 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 140 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1999 | 145 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 1999 | 195 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2005 | 2905 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 1570 | 0.010 |
Why?
|